...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lymphology >Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer (see comments)
【24h】

Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer (see comments)

机译：两种不同香豆素剂量在治疗乳腺癌后治疗手臂淋巴水肿的临床疗效比较研究（见评论）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In a randomized, double-blind, parallel group study, we compared the clinical efficacy of coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women (age 35-65 years) with lymphedema of the upper limb secondary to surgery and irradiation for treatment of breast cancer. During 12 months of coumarin therapy, the arm volume of lymphedema and a clinical score (degree of arm edema, heaviness, hardness, and neuralgia/dysesthesia) were determined. In both groups, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B) (N.S.), the overall clinical score improved (12.9 +/- 4.3 to 5.7 +/- 3.5 in Group A and from 11.7 +/- 3.7 to 4.7 +/- 3.9 in Group B) (N.S.), and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B) (N.S.). Only mild to moderate side effects of drug therapy were recorded. Coumarin prevents a spontaneous trend toward an increase in arm lymphedema after treatment of breast cancer, decreases the severity of local symptoms, and overall improves the quality of life. No difference was found between the apparent benefits of coumarin at 90 mg/day compared with 135 mg/day.
机译：在一项随机，双盲，平行组研究中，我们比较了90毫克/天香豆素（A组）和135毫克/天（B组）在77例女性淋巴水肿中的临床疗效（35-65岁）上肢继发于手术和放射治疗乳腺癌。在香豆素治疗的12个月中，确定了手臂的淋巴水肿量和临床评分（手臂水肿的程度，沉重，硬度和神经痛/感觉异常）。在两组中，手臂淋巴水肿的量均减少（A组为14.9％，B组为13.2％）（NS），总体临床评分有所改善（A组从12.9 +/- 4.3降至5.7 +/- 3.5，从11.7降低了） B组（NS）为+/- 3.7至4.7 +/- 3.9，香豆素的总体疗效相似或良好（A组为71.9％，B组为68.6％）（NS）。仅记录了药物治疗的轻度至中度副作用。香豆素可预防乳腺癌治疗后手臂淋巴水肿增加的自发趋势，降低局部症状的严重程度，并总体上改善生活质量。 90毫克/天的香豆素与135毫克/天的表观益处之间没有发现差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号